Additionally, glutamine metabolism supports the mitochondrial functions and cellular redox metabolic capacity of AML cells, resulting in the adverse prognosis of AML patients carrying the FLT3-ITD mutation. This evidence concerns the gene FLT3 and acute myeloid leukemia.